Unknown

Dataset Information

0

Synthesis of the Anionic Hydroxypropyl-?-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.


ABSTRACT: Niemann-Pick type C disease (NPC) is a lysosomal storage disease that is characterized by a progressive accumulation of unesterified cholesterol in the lysosomes leading to organ damage from cell dysfunction. Hydroxypropyl-?-cyclodextrin (HP-?-CD) is an attractive drug candidate for treating NPC, as it diminishes cholesterol accumulation in NPC cells. Systemic HP-?-CD treatment, however, is limited by rapid renal clearance. We designed a new anionic HP-?-CD polyrotaxane to act as a slow release formulation based on a polyalkylene phosphate core to improve the pharmacokinetics. The polyalkylene phosphate comprises hydrophobic decamethylene spacers linked by biodegradable anionic phosphodiester bonds. HP-?-CD was threaded onto this polymer first and ?-CD afterwards to prevent burst release of the threaded HP-?-CD. Our findings show that HP-?-CD was slowly released from the watersoluble polyrotaxane over a 30 days period. The polyrotaxane provided persistently diminished cholesterol levels in NPC1 cells by 20% relative to untreated cells. These results demonstrate the therapeutic potential of this novel HP-?-CD polyrotaxane for the mobilization of aberrantly stored cholesterol in NPC1 cells.

SUBMITTER: Egele K 

PROVIDER: S-EPMC6675466 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.

Egele Kerstin K   Samaddar Shayak S   Schneider Nina N   Thompson David D   Wenz Gerhard G  

Journal of materials chemistry. B 20181207 4


Niemann-Pick type C disease (NPC) is a lysosomal storage disease that is characterized by a progressive accumulation of unesterified cholesterol in the lysosomes leading to organ damage from cell dysfunction. Hydroxypropyl-β-cyclodextrin (HP-β-CD) is an attractive drug candidate for treating NPC, as it diminishes cholesterol accumulation in NPC cells. Systemic HP-β-CD treatment, however, is limited by rapid renal clearance. We designed a new anionic HP-β-CD polyrotaxane to act as a slow release  ...[more]

Similar Datasets

| S-EPMC3308731 | biostudies-literature
| S-EPMC5857219 | biostudies-literature
| S-EPMC6598286 | biostudies-literature
| S-EPMC6679735 | biostudies-literature
| S-EPMC5004151 | biostudies-literature
| S-EPMC6062155 | biostudies-literature
| S-EPMC3175325 | biostudies-literature
| S-EPMC6170477 | biostudies-literature
| S-EPMC6805667 | biostudies-literature
| S-EPMC6906155 | biostudies-literature